"The upside to my short position was small, but the risk was huge," he said, adding that he had become increasingly concerned with the short thesis, especially after the FDA didn't send Abraxane to an advisory panel.The Abraxane "event" is high-risk, but one thing is fairly certain, with American Pharmaceutical shares already rising and the short position still high, the stock is likely to surge in one direction or the other, depending on the FDA's decision.
Gambling on American Pharma Partners
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts